A comparison of two doses of melperone, an atypical antipsychotic drug, in the treatment of schizophrenia

Schizophrenia Research

Volumn 62, Issue 1-2, 2003, Pages 65-72

  Sumiyoshi, Tomiki ^a   Jayathilake, Karu ^a   Meltzer, Herbert Y ^a  

^a Psychiatric Hospital at Vanderbilt   (United States)

Author keywords

Atypical antipsychotic drug; Dose dependency; Extrapyramidal symptoms; Melperone; Schizophrenia

Indexed keywords

MELPERONE;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; EVALUATION; FEMALE; HOSPITAL ADMISSION; HUMAN; MALE; MENTAL DISEASE; MENTAL HOSPITAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0038064458     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(02)00351-1     Document Type: Article

References (48)

1. Alvir J.M., Lieberman J.A., Safferman A.Z., Schwimmer J.L., Schaaf J.A. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N. Engl. J. Med. 329:1993;162-167.
2. Andreasen N.C. Scale for the Assessment of Negative Symptoms (SANS). 1983;University of Iowa, Iowa City.
3. Asberg M., Montgomery S.A., Perris C., Schalling D., Sedvall G. A comprehensive psychopathological rating scale. Acta Psychiatr. Scand. 271:1978;5-27. Suppl.
4. Barbato L., Monge A., Stocchi F., Nordera G. Melperone in the treatment of iatrogenic psychosis in Parkinson's disease. Funct. Neurology. 11:1996;201-207.
5. Bjerkenstedt L. Melperone in the treatment of schizophrenia. Acta Psychiatr. Scand. 352:1989;35-39. Suppl.
6. Bjerkenstedt L., Eneroth P., Harnryd C., Sedvall G. Effects of melperone and thiothixene on prolactin levels in cerebrospinal fluid and plasma of psychotic women. Arch. Psychiatr. Nervenkr. 224:1977;281-293.
7. Bjerkenstedt L., Harnryd C., Grimm V., Gullberg B., Sedvall G. A double-blind comparison of melperone and thiothixene in psychotic women using a new rating scale, the CPRS. Arch. Psychiatr. Nervenkr. 226:1978;157-172.
8. Campbell M., Young P.I., Bateman D.N., Smith J.M., Thomas S.H. The use of atypical antipsychotics in the management of schizophrenia. Br. J. Clin. Pharmacol. 47:1999;13-22.
9. Christensen I., Geismar L., Kirkegaard A., Kirkegaard G. Additional studies on side effects of melperone in long-term therapy for 1-20 years in psychiatric patients. Arzneimittelforschung. 36:1986;855-860.
10. Costa D.C., Pilowsky L.S., Ell P.J. Nuclear medicine in neurology and psychiatry. Lancet. 354:1999;1107-1111.
11. Dewey R.B. Jr., O'Suilleabhain P.E. Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease. Neurology. 55:2000;1753-1754.
12. Endicott J., Spitzer R.L. A diagnostic interview: the schedule for affective disorder and schizophrenia. Arch. Gen. Psychiatry. 35:1978;837-844.
13. Endicott J., Spitzer R.L., Fleiss J.L., Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch. Gen. Psychiatry. 33:1976;766-771.
14. Friedman J.H., Factor S.A. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov. Disord. 15:2000;201-211.
15. Gudelsky G.A., Meltzer H.Y. Activation of tuberoinfundibular dopamine neurons following the acute administration of atypical antipsychotics. Neuropsychopharmacology. 2:1989;45-51.
16. Gunne L.M., Barany S. A monitoring test for the liability of neuroleptic drugs to induce tardive dyskinesia. Psychopharmacology (Berl.). 63:1979;195-198.
17. Gunne L.M., Johansson P. Chronic melperone administration does not enhance oral movements in rats. Acta Psychiatr. Scand. 352:1989;48-50. Suppl.
18. Guy W. ECDEU Assessment Manual for Psychopharmacology, Publication ADM 76-338. 1976;534-537 United States Department of Health, Education and Welfare, Washington, DC.
19. Harnryd C., Bjerkenstedt L., Gullberg B. A clinical comparison of melperone and placebo in schizophrenic women on a milieu therapeutic ward. Acta Psychiatr. Scand. 352:1989;40-47. Suppl.
20. Ichikawa J., Dai J., O'Laughlin I.A., Fowler W.L., Meltzer H.Y. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology. 26:2002;325-339.
21. Kane J., Honigfeld G., Singer J., Meltzer H.Y., Group C.C.S. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry. 45:1988;789-796.
22. Kapur S., Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J. Psychiatry Neurosci. 25:2000;161-166.
23. Kapur S., Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?: a new hypothesis. Am. J. Psychiatry. 158:2001;360-369.
24. Kinon B.J., Basson B.R., Gilmore J.A., Tollefson G.D. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J. Clin. Psychiatry. 62:2001;92-100.
25. Kirkegaard A., Kirkegaard G., Geismar L., Christensen I. Additional studies on side effects of melperone in long-term therapy for 1 to 15 years in psychiatric patients. Arzneimittelforschung. 31:1981;737-740.
26. Kraus T., Haack M., Schuld A., Hinze-Selch D., Kuhn M., Uhr M., Pollmacher T. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am. J. Psychiatry. 156:1999;312-314.
27. Kuroki T., Meltzer H.Y., Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J. Pharmacol. Exp. Ther. 288:1999;774-781.
28. Lowy M.T., Koenig J.I., Meltzer H.Y. Stimulation of serum cortisol and prolactin in man by MK-212, a centrally active serotonin agonist. Biol. Psychiatry. 23:1988;818-828.
29. Meltzer H.Y. Treatment of schizophrenia and spectrum disorders: pharmacotherapy, psychosocial treatments, and neurotransmitter interactions. Biol. Psychiatry. 46:1999;1321-1327.
30. Meltzer H.Y., McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 25:1999;233-255.
31. Meltzer H.Y., Fang V.S., Young M.A. Clozapine-like drugs. Psychopharmacol. Bull. 16:1980;32-35.
32. Meltzer H.Y., Alphs L.D., Bastani B., Ramirez L. Effect of melperone in treatment-resistant schizophrenia. Stefanis C.N., Soldatos C.R., Rabavilas A.D. VIII World Congress of Psychiatry Abstracts. vol. 899:1989;502 Excerpta Medica, Amsterdam.
33. Meltzer H.Y., Koenig J.I., Nash J.F., Gudelsky G.A. Melperone and clozapine: neuroendocrine effects of atypical neuroleptic drugs. Acta Psychiatr. Scand. 352:1989;24-29. Suppl.
34. 2 pKi values. J. Pharmacol. Exp. Ther. 251:1989;238-246.
35. Meltzer H.Y., Matsubara S., Lee J.C. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol. Bull. 25:1989;390-392.
36. Meltzer H.Y., O'Laughlin I.A., Dai J., Fowler W.L., Ichikawa J. Atypical antipsychotic drugs (APD) but not typical APD increased extracellular acetylcholine (Ach-ext) levels in rat medialprefrontal cortex in the absence of Achesterase (AchE) inhibition. Soc. Neurosci. Abstr. 25(Pt. 1):1999;452.
37. Meltzer H.Y., Sumiyoshi T., Jayathilake K. Melperone in the treatment of neuroleptic-resistant schizophrenia. Psychiatry Res. 105:2001;201-209.
38. Overall J.E., Gorham D.R. The brief psychiatric rating scale. Psychol. Rep. 10:1962;799-812.
39. Parada M.A., Hernandez L., Puig de Parada M., Rada P., Murzi E. Selective action of acute systemic clozapine on acetylcholine release in the rat prefrontal cortex by reference to the nucleus accumbens and striatum. J. Pharmacol. Exp. Ther. 281:1997;582-588.
40. Peuskens, J., 1995. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br. J. Psychiatry 166, 712-726; discussion 727-733.
41. Poldinger W.J. Melperone in low doses in anxious neurotic patients. A double-blind placebo-controlled clinical study. Neuropsychobiology. 11:1984;181-186.
42. Seeman P., Tallerico T. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol. Psychiatry. 3:1998;123-134.
43. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. 212:1970;11-19. Suppl.
44. 2 receptors. J. Pharmacol. Exp. Ther. 266:1993;1374-1384.
45. Sumiyoshi T., Hasegawa M., Jayathilake K., Meltzer H.Y. Prediction of short-term changes in symptom severity by baseline plasma homovanillic acid levels in schizophrenic patients receiving clozapine. Psychiatry Res. 69:1997;113-121.
46. Sumiyoshi T., Hasegawa M., Jayathilake K., Meltzer H.Y. Sex differences in plasma homovanillic acid levels in schizophrenia and normal controls: relation to neuroleptic resistance. Biol. Psychiatry. 41:1997;560-566.
47. Sumiyoshi, T., Jayathilake, K., Meltzer, H.Y. The effect of melperone, an atypical antipsychotic drug, on cognitive function in schizophrenia. Schizophr. Res. (in press).
48. Wiesel F.A., Farde L., Halldin C. Clinical melperone treatment blocks D2-dopamine receptors in the human brain as determined by PET. Acta Psychiatr. Scand. 352:1989;30-34. Suppl.